Sareum, Roche to accelerate cancer drug research

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Sareum Holdings plc formed an agreement with Roche to provide protein structure determination capabilities to accelerate Roche's cancer drug-discovery research.

Financial terms of the agreement were not disclosed.

Cambridge, U.K.-based Sareum will provide detailed structural information on how Roche's potential drug candidates interact with target receptor proteins to help Roche scientists identify cancer therapeutics.

Sareum is a structure-based drug-discovery business.

Roche is a Nutley, N.J., pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.